image
Healthcare - Biotechnology - NASDAQ - US
$ 285.73
1.06 %
$ 6.34 B
Market Cap
-16.01
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one MDGL stock under the worst case scenario is HIDDEN Compared to the current market price of 286 USD, Madrigal Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one MDGL stock under the base case scenario is HIDDEN Compared to the current market price of 286 USD, Madrigal Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one MDGL stock under the best case scenario is HIDDEN Compared to the current market price of 286 USD, Madrigal Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MDGL

image
$360.0$360.0$350.0$350.0$340.0$340.0$330.0$330.0$320.0$320.0$310.0$310.0$300.0$300.0$290.0$290.0$280.0$280.0$270.0$270.0$260.0$260.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
180 M REVENUE
0.00%
-498 M OPERATING INCOME
-30.85%
-466 M NET INCOME
-24.69%
-456 M OPERATING CASH FLOW
-40.51%
-274 M INVESTING CASH FLOW
45.40%
735 M FINANCING CASH FLOW
23.52%
137 M REVENUE
32.84%
-79.3 M OPERATING INCOME
-18.38%
-73.2 M NET INCOME
-23.26%
-88.9 M OPERATING CASH FLOW
14.93%
164 M INVESTING CASH FLOW
441.77%
8.64 M FINANCING CASH FLOW
-56.30%
Balance Sheet Madrigal Pharmaceuticals, Inc.
image
Current Assets 1.03 B
Cash & Short-Term Investments 926 M
Receivables 53.8 M
Other Current Assets 52.9 M
Non-Current Assets 9.32 M
Long-Term Investments 0
PP&E 4.59 M
Other Non-Current Assets 4.73 M
88.87 %5.16 %5.07 %Total Assets$1.0b
Current Liabilities 169 M
Accounts Payable 43.6 M
Short-Term Debt 983 K
Other Current Liabilities 125 M
Non-Current Liabilities 119 M
Long-Term Debt 119 M
Other Non-Current Liabilities 0
15.15 %43.32 %41.20 %Total Liabilities$287.9m
EFFICIENCY
Earnings Waterfall Madrigal Pharmaceuticals, Inc.
image
Revenue 180 M
Cost Of Revenue 6.23 M
Gross Profit 174 M
Operating Expenses 672 M
Operating Income -498 M
Other Expenses -32 M
Net Income -466 M
200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)180m(6m)174m(672m)(498m)32m(466m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
96.54% GROSS MARGIN
96.54%
-276.39% OPERATING MARGIN
-276.39%
-258.64% NET MARGIN
-258.64%
-61.76% ROE
-61.76%
-44.70% ROA
-44.70%
-56.97% ROIC
-56.97%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Madrigal Pharmaceuticals, Inc.
image
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)(450m)(450m)(500m)(500m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -466 M
Depreciation & Amortization 696 K
Capital Expenditures -1.46 M
Stock-Based Compensation 79.9 M
Change in Working Capital -72.3 M
Others 2.08 M
Free Cash Flow -457 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Madrigal Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for MDGL of $397 , with forecasts ranging from a low of $336 to a high of $420 .
MDGL Lowest Price Target Wall Street Target
336 USD 17.59%
MDGL Average Price Target Wall Street Target
397 USD 38.88%
MDGL Highest Price Target Wall Street Target
420 USD 46.99%
Price
Max Price Target
Min Price Target
Average Price Target
450450400400350350300300250250200200Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Madrigal Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
25.8 M USD 9
6-9 MONTHS
5.8 M USD 3
9-12 MONTHS
1.55 M USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease noncirrhotic MASH who have moderate to advanced fibrosis. marketwatch.com - 6 days ago
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of resmetirom (Rezdiffra) for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The European Commission decision is anticipated in August. globenewswire.com - 6 days ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2025 to 36 new non-executive employees as equity inducement awards under the terms of Madrigal's 2023 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 1 week ago
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT. globenewswire.com - 3 weeks ago
In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals Madrigal Pharmaceuticals' Rezdiffra for NASH achieved $137.3M in Q1 '25 sales, surpassing analyst estimates and indicating strong growth, but the stock hasn't rallied. Near-term catalysts include potential approval of Rezdiffra in Europe, Q2 '25 earnings and business development, with MDGL indicating they are keen to add to their pipeline. Results from the MAESTRO-NASH OUTCOMES trial are not expected until 2027, but recent data from MAESTRO-NAFLD-1 provide some hint of the potential efficacy of Rezdiffra in some patients with cirrhosis. seekingalpha.com - 1 month ago
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra. Patients (n=122) in the study achieved significant improvements from baseline in liver stiffness, liver fat, fibrosis biomarkers, liver volume and risk scores for clinically significant portal hypertension (CSPH). globenewswire.com - 1 month ago
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra Madrigal Pharmaceuticals has a first-mover advantage in the huge MASH market due to the approval of Rezdiffra just over a year ago. The initial rollout of the compound is encouraging, and the company is expecting a huge surge in revenues in FY2025. Most analyst firms are positive around the company's prospects, and Madrigal has some potential additional catalysts on the horizon. seekingalpha.com - 1 month ago
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - Chief Executive Officer and Director Mardi Dier - Chief Financial Officer Conference Call Participants Eliana Merle - UBS Andrea Newkirk - Goldman Sachs Ritu Baral - TD Cowen Akash Tewari - Jefferies Yasmeen Rahimi - Piper Sandler Liisa Bayko - Evercore Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Prakhar Agrawal - Cantor Fitzgerald Operator Good day, and thank you for standing by. seekingalpha.com - 1 month ago
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales. zacks.com - 1 month ago
Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates Madrigal (MDGL) came out with a quarterly loss of $3.32 per share versus the Zacks Consensus Estimate of a loss of $3.62. This compares to loss of $7.38 per share a year ago. zacks.com - 1 month ago
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports first-quarter 2025 financial results and provides corporate updates. globenewswire.com - 1 month ago
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. globenewswire.com - 1 month ago
8. Profile Summary

Madrigal Pharmaceuticals, Inc. MDGL

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 6.34 B
Dividend Yield 0.00%
Description Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Contact Four Tower Bridge, West Conshohocken, PA, 19428 https://www.madrigalpharma.com
IPO Date Feb. 6, 2007
Employees 528
Officers Ms. Tina E. Ventura Chief Investor Relations Officer Mr. Mark Underwood Executive Vice President of Business Planning & Operations Ms. Mardi C. Dier Executive Vice President & Chief Financial Officer Ms. Shannon Kelley Executive Vice President, Chief Legal Officer & Corporate Secretary Ms. Carole Huntsman Executive Vice President & Chief Commercial Officer Mr. Ronald Filippo Executive Vice President & Chief Information Officer Mr. Clint Wallace Executive Vice President & Chief Human Resources Officer Dr. Rebecca A. Taub M.D. Founder, Senior Scientific & Medical Advisor and Director Mr. William J. Sibold Chief Executive Officer, President & Director Mr. Edward Chiang Senior Vice President of Clinical & Technical Operations